QUOTE AND NEWS
Benzinga  May 13  Comment 
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX7353 in healthy volunteers. Discovered by BioCryst,...
Benzinga  May 11  Comment 
In a report published Monday, Oppenheimer analysts maintained a Perform rating on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), saying that clinical data could drive the stock higher in 2H15. BioCryst reported its 1Q15 revenue and EPS at...
Benzinga  Apr 20  Comment 
Bank of America upgraded BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) from Underperform to Neutral. BioCryst Pharmaceuticals shares have surged 8.19 percent over the past 52 weeks, while the S&P 500 index has gained 11.18 percent in the same...
Benzinga  Apr 20  Comment 
Motley Fool  Apr 1  Comment 
BioCryst shares launch higher for a second straight day following a substantial contract win from the U.S. government.
TheStreet.com  Mar 31  Comment 
NEW YORK (TheStreet) -- BioCryst Pharmaceuticals shares are up 2.8% to $8.81 in early market trading on Tuesday after the company announced that it won a U.S. government contract to continue to develop its treatment for Ebola and other...
Benzinga  Mar 31  Comment 
Charter Communications, Inc. (NASDAQ: CHTR) shares surged 6.33% to $195.00 in pre-market trading. Charter has agreed to purchase Bright House Networks for $10.4 billion, according to Reuters. Movado Group, Inc. (NYSE: MOV) shares gained 6.32%...
Benzinga  Feb 18  Comment 
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) reported a narrower-than-expected loss for the fourth quarter. The Durham, North Carolina-based company posted a quarterly loss of $11.7 million, or $0.16 per share, versus a year-ago net loss of $5.4...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki